Technology | March 31, 2011

Oncology Information System Features New Interface

Oncology Information System Features New Interface

March 31, 2011 – An oncology information system now includes an interface to radiotherapy systems. Elekta’s Mosaiq version 2.20 now has an interface to Xstrahl’s superficial and orthovoltage radiotherapy systems, enabling users of these therapy machines to prepare, deliver and record treatments via Mosaiq.

The Xstrahl family of treatment systems treats superficial tumors and benign lesions (e.g., basal cell and squamous cell carcinomas, keloid scars and dermatological conditions) with low-energy radiation.

The first two users, Sequoia Hospital in Redwood City, Calif., and St. James’s University Hospital, in Leeds, U.K., have reported success at their institutions.

“Mosaiq 2.20 is recording and verifying the treatments we’re giving patients, which is very important to us,” says Helen Monk, manager, radiation oncology at Sequoia Hospital. “Mosaiq helps ensure that every step we’re taking is correct. If a setting or filter has somehow been set incorrectly on the Xstrahl system, the machine will not turn on because it does not match what we set in Mosaiq. If you’re working by yourself, it’s nice to have that added comfort knowing that Mosaiq is double-checking everything you do to ensure safety.”

St. James’s University Hospital’s Peter Enever, advanced practitioner, agrees with the added assurance of safety that the new interface brings.

“You can’t get the combination of filters and applicators wrong,” he said. “The intelligent ‘engine’ in Mosaiq automatically drives the workflow and checks that each step has been done correctly. From our point of view that is a very good safety feature and it gives users added confidence in what they’re doing.”

Enever added that the interface’s similarity to that of a linear accelerator made training literally a five-minute process. “It looks and behaves exactly the same way as a linac interface,” he said. “St. James’s Institute of Oncology’s aspiration to achieve a single integrated patient pathway has moved one step closer with the introduction of the MOSAIQ-Xstrahl interface.”

For more information: www.elekta.com

Related Content

A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.